<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Temozolomide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Temozolomide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Temozolomide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9699" href="/d/html/9699.html" rel="external">see "Temozolomide: Drug information"</a> and <a class="drug drug_patient" data-topicid="11074" href="/d/html/11074.html" rel="external">see "Temozolomide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F225270"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Temodar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868346"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Temozolomide;</li>
<li>JAMP-Temozolomide;</li>
<li>TARO-Temozolomide;</li>
<li>Temodal;</li>
<li>Teva-Temozolomide</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1050179"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Alkylating Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F12704784"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Temozolomide is associated with a low or moderate emetic potential depending on dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637','lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637','lexi-content-ref-30729654'])">Ref</a></span>); antiemetics may be recommended to prevent nausea and vomiting. Prior to dosing, ANC should be ≥1,500/mm<sup>3</sup> and platelets ≥100,000/mm<sup>3</sup>. Dose, frequency, number of doses, and start date may vary by protocol and treatment phase. Refer to individual protocols.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="130c3e8f-5b0a-41a6-a1bc-76e68507c424">Ewing sarcoma, recurrent or progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma, recurrent or progressive:</b> Limited data available: Children ≥2 years and Adolescents: Oral: 100 mg/m<sup>2</sup>/dose once daily for 5 days, repeat cycle every 21 days (in combination with irinotecan; administer 1 hour prior to irinotecan) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19637327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19637327'])">Ref</a></span>); dosing based on a retrospective review.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6fc7672-3ba1-4f98-9c9e-f6cd53c46ea2">Neuroblastoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma</b>
<b>, relapsed or refractory:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Irinotecan regimen: </i>Infants, Children, and Adolescents: Oral: 100 mg/m<sup>2</sup>/dose once daily for 5 days, repeat cycle every 21 days for up to 6 cycles; in combination with irinotecan; administer 1 hour prior to irinotecan (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21115869']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21115869'])">Ref</a></span>). <b>Note:</b> Temozolomide doses were rounded to the nearest capsule size.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Topotecan regimen (TOTEM): </i>Infants ≥6 months, Children, and Adolescents: Oral: 150 mg/m<sup>2</sup>/dose on days 1 to 5 every 28 days; in combination with topotecan; administer prior to the topotecan; continue until disease progression or unacceptable toxicity up to a maximum of 12 months; doses were reduced for hematologic toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24021349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24021349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single agent: </i>Children ≥3 years and Adolescents: Oral: Administer doses on days 1 to 5 every 21 to 28 days; continue until disease progression or unacceptable toxicity up to a maximum of 24 cycles; doses were reduced by 25% for grade 4 thrombocytopenia or neutropenia, and grade 3 or 4 mucositis, documented sepsis, pulmonary distress/infiltrate, or seizures requiring prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16047361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16047361'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">No prior craniospinal irradiation: Oral: 215 mg/m<sup>2</sup>/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Previous craniospinal irradiation or relapse after bone-marrow transplant: Oral: 180 mg/m<sup>2</sup>/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7177d86f-32ee-49d7-9ed7-ee88e7f0a1c0">Solid tumors, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors, relapsed/refractory</b>
<b> (including but not limited to brain tumor [astrocytomas, gliomas, medulloblastoma], neuroblastoma, and sarcomas)</b>: Limited data available; efficacy results variable: Infants, Children, and Adolescents: Oral: 200 to 215 mg/m<sup>2</sup>/dose days 1 to 5 every 21 to 28 days; dose was decreased to 180 mg/m<sup>2</sup>/dose for patients who received prior craniospinal irradiation or relapsed after bone marrow transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16047361','lexi-content-ref-17705175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16047361','lexi-content-ref-17705175'])">Ref</a></span>); in other trials, lower doses of 160 to 200 mg/m<sup>2</sup>/dose once daily for 5 days every 28 days were used in patients 3 to 18 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192856"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; refer to individual protocols if available. Based on experience in adult patients with mild to moderate renal impairment, no effect on temozolomide clearance was demonstrated; in severe impairment and dialysis, use with caution; has not been adequately studied.</p></div>
<div class="block dohp drugH1Div" id="F51192857"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; refer to individual protocols if available. Based on experience in adult patients, use with caution; has not been adequately studied.</p></div>
<div class="block doa drugH1Div" id="F225272"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9699" href="/d/html/9699.html" rel="external">see "Temozolomide: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> ANC should be ≥1,500/mm<sup>3</sup> and platelets ≥100,000/mm<sup>3</sup> prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Premedication:</i> Temozolomide is associated with a moderate or high emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>); antiemetics are recommended to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i>
<i>Pneumocystis jirovecii</i> pneumonia (PCP) prophylaxis is required during concomitant radiation therapy phase for all patients with newly diagnosed glioblastoma; continue PCP prophylaxis in patients who develop lymphocytopenia until lymphocyte recovery to ≤ grade 1.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4dc87e40-cc27-4d02-9261-f78ac6d1e079">Anaplastic astrocytoma, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaplastic astrocytoma, newly diagnosed:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant therapy (beginning 4 weeks after the completion of radiotherapy): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cycle 1:</i>
<b>Oral, IV: </b>150 mg/m<sup>2</sup> once daily on days 1 to 5 of the 28-day treatment cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cycles 2 to 6 (</i>
<i>if cycle 1 is tolerated with no or minimal toxicity): </i>
<b>Oral, IV: </b>200 mg/m<sup>2</sup> once daily on days 1 to 5 of subsequent 28-day treatment cycles for a total of 6 cycles. If dose was not escalated at the onset of cycle 2, do not increase for cycles 3 to 6.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Concurrent radiation followed by adjuvant therapy (off-label):</i>
<b>Oral:</b> 75 mg/m<sup>2</sup> once daily for a maximum of 7 weeks during radiation therapy and then (adjuvant therapy; beginning 4 weeks after completion of radiation therapy) 150 mg/m<sup>2</sup> once daily for 5 days of a 28-day treatment cycle in cycle 1, followed by 200 mg/m<sup>2</sup> once daily for 5 days of subsequent 28-day treatment cycles for up to a total of 12 adjuvant cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28801186','lexi-content-ref-34000245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28801186','lexi-content-ref-34000245'])">Ref</a></span>). Refer to protocols for dosage adjustment details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3f7c333-eb9e-4c02-87aa-52d369ba7f24">Anaplastic astrocytoma, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaplastic astrocytoma, refractory:</b>
<b>Oral, IV:</b> Initial dose: 150 mg/m<sup>2</sup> once daily on days 1 to 5 of a 28-day cycle. If ANC ≥1,500/mm<sup>3</sup> and platelets ≥100,000/mm<sup>3</sup> at the nadir and on day 1 of the next cycle, increase dose to 200 mg/m<sup>2</sup> on days 1 to 5 of a 28-day cycle and continue until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad7b6e17-ddc8-4e9f-aaca-c982d2777d38">Anaplastic oligoastrocytoma or anaplastic oligodendroglioma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaplastic oligoastrocytoma or anaplastic oligodendroglioma (off-label use): Oral:</b> 200 mg/m<sup>2</sup> once daily on days 1 to 5 of a 28-day treatment cycle for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19901110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19901110'])">Ref</a></span>) <b>or</b> 200 mg/m<sup>2</sup> once daily on days 1 to 5 of a 28-day treatment cycle for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20406900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20406900'])">Ref</a></span>) <b>or</b> (in patients with chromosome 1p/19q loss) 150 mg/m<sup>2</sup> once daily for 5 days of a 28-day treatment cycle in cycles 1 and 2, followed by 200 mg/m<sup>2</sup> once daily for 5 days of subsequent 28-day treatment cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19011763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19011763'])">Ref</a></span>) <b>or</b> (in patients without chromosome 1p/19q loss) 150 mg/m<sup>2</sup> once daily for 5 days of a 28-day treatment cycle in cycles 1 and 2, followed by 200 mg/m<sup>2</sup> once daily for 5 days for up to two 28-day cycles, followed by 75 mg/m<sup>2</sup> once daily during radiation therapy, and then followed by post-radiation temozolomide treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19011763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19011763'])">Ref</a></span>) <b>or</b> 150 to 200 mg/m<sup>2</sup> once daily for 5 days of a 28-day treatment cycle for a maximum of 12 cycles in patients with a complete response or until disease progression in patients with partial response or stable disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16954518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16954518'])">Ref</a></span>). Refer to protocols for dosage adjustment details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0456492-d8e0-44af-8602-9c3e236c97e5">Astrocytoma or oligodendroglioma, low grade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Astrocytoma or oligodendroglioma, low grade (off-label use): Oral:</b> 75 mg/m<sup>2</sup> once daily during radiation therapy and then (adjuvant therapy) 150 to 200 mg/m<sup>2</sup> once daily for 5 days of a 28-day treatment cycle for up to 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25680596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25680596'])">Ref</a></span>) <b>or</b> (protracted single-agent therapy) 75 mg/m<sup>2</sup> once daily for 21 days of a 28-day treatment cycle for 12 to 15 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17082887']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17082887'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a743e782-1cf9-4246-acd0-3c533d7d2969">CNS metastases from solid tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS metastases from solid tumors (off-label use): Oral:</b> 150 mg/m<sup>2</sup> (200 mg/m<sup>2</sup> in chemotherapy-naïve patients) once daily for 5 days of a 28-day treatment cycle until disease progression or unacceptable toxicity up to a maximum of 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15169796']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15169796'])">Ref</a></span>) <b>or</b> 150 mg/m<sup>2</sup> (200 mg/m<sup>2</sup> in chemotherapy-naïve patients) once daily for 5 days of a 28-day treatment cycle until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11718258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11718258'])">Ref</a></span>) <b>or</b> 150 mg/m<sup>2</sup> once daily for 5 days of a 28-day treatment cycle until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11300333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11300333'])">Ref</a></span>) <b>or</b> 150 mg/m<sup>2</sup> once daily on days 1 to 7 and days 15 to 21 of a 28-day or 35-day treatment cycle until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19767314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19767314'])">Ref</a></span>) <b>or</b> 150 mg/m<sup>2</sup> once daily on days 1 to 7 and days 15 to 21 of a 28-day treatment cycle for a maximum of 2 cycles after complete response, until disease progression or for 4 cycles after stable partial response, 6 cycles after stable disease, or until unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16565212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16565212'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86f6a699-dcb9-4686-a4db-35ac0eb8b8fc">Cutaneous T-cell lymphoma, mycosis fungoides and Sézary syndrome, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous T-cell lymphoma, mycosis fungoides and Sézary syndrome, advanced (off-label use):</b>
<b>Oral:</b> 200 mg/m<sup>2</sup> once daily for 5 days every 28 days for up to 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21747120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21747120'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="130c3e8f-5b0a-41a6-a1bc-76e68507c424">Ewing sarcoma, recurrent or progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma, recurrent or progressive (off-label use):</b>
<b>Oral:</b> 100 mg/m<sup>2</sup>/dose on days 1 to 5 every 21 days (in combination with irinotecan) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19637327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19637327'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f23de36d-6365-4527-8697-940d490e0c34">Glioblastoma, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glioblastoma, newly diagnosed:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Concomitant phase:</b></i>
<b>Oral, IV:</b> 75 mg/m<sup>2</sup> once daily for 42 to 49 days (in combination with focal radiotherapy of 60 Gy administered in 30 fractions to the tumor bed or resection site with a 2- to 3-cm margin).</p>
<p style="text-indent:-2em;margin-left:6em;">Continue at 75 mg/m<sup>2</sup> once daily throughout the 42- to 49-day concomitant phase as long as ANC ≥1,500/mm<sup>3</sup>, platelets ≥100,000/mm<sup>3</sup>, and nonhematologic toxicity ≤ grade 1 (excludes alopecia, nausea/vomiting).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Maintenance phase:</i></b> Begin 4 weeks after concomitant phase completion.</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>Oral, IV: </b>150 mg/m<sup>2</sup> once daily on days 1 to 5 of the 28-day treatment cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 to 6: <b>Oral, IV: </b>May increase to 200 mg/m<sup>2</sup> once daily on days 1 to 5; repeat every 28 days for a total of 6 cycles (if ANC ≥1,500/mm<sup>3</sup>, platelets ≥100,000/mm<sup>3</sup>, and nonhematologic toxicities for cycle 1 are ≤ grade 2 [excludes alopecia, nausea/vomiting]). If dose was not escalated at the onset of cycle 2, do not increase for cycles 3 to 6.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapy:</i> A retrospective analysis of 4 randomized studies in patients with newly diagnosed glioblastoma who were progression free following 6 cycles of adjuvant temozolomide therapy determined that continued administration beyond 6 cycles did not demonstrate improvement in overall survival (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28371907']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28371907'])">Ref</a></span>). In a randomized study in patients with stable disease after 6 cycles, those randomized to a total of 12 temozolomide cycles had similar progression free and overall survival as the patients who stopped after 6 cycles; however, toxicities, including lymphopenia, thrombocytopenia, and nausea/vomiting, were higher in the patients who continued temozolomide beyond 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32328662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32328662'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="45f6ac09-4299-4d36-9deb-439e0fb593ac">Glioblastoma, recurrent, relapsed, or progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glioblastoma, recurrent, relapsed, or progressive (off-label use):</b>
<b>Oral:</b> 200 mg/m<sup>2</sup> once daily for 5 days every 28 days; if previously treated with chemotherapy, initiate at 150 mg/m<sup>2</sup> once daily for 5 days every 28 days and increase to 200 mg/m<sup>2</sup> once daily for 5 days every 28 days with cycle 2 if no hematologic toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11300335','lexi-content-ref-10944597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11300335','lexi-content-ref-10944597'])">Ref</a></span>) <b>or</b> 200 mg/m<sup>2</sup> once daily for 5 days every 28 days for up to 9 cycles or until disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20855843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20855843'])">Ref</a></span>) <b>or</b> 150 mg/m<sup>2</sup> once daily on days 1 to 7 and days 15 to 21 of a 28-day treatment cycle for a maximum of 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17664483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17664483'])">Ref</a></span>) <b>or</b> 50 mg/m<sup>2</sup> once daily for a maximum of 12 months or until disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20308655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20308655'])">Ref</a></span>) <b>or</b> 50 mg/m<sup>2</sup> once daily until disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23243055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23243055'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18caf99b-f195-4f15-b158-71b62bb2404f">Melanoma, metastatic malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, metastatic malignant (off-label use):</b>
<b>Oral:</b> 200 mg/m<sup>2</sup> once daily for 5 days every 28 days (for up to 12 cycles in the absence of disease progression or unacceptable toxicity). Reduce the dose by 25% in subsequent cycles for grade 3 or 4 hematologic toxicity and reduce the dose by 50% for grade 3 or 4 nonhematologic toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10623706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10623706'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bec6b935-37a5-4673-b645-664aedbd0c66">Pancreatic neuroendocrine tumors, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic neuroendocrine tumors, advanced (off-label use): Oral:</b> 150 mg/m<sup>2</sup> once daily for 7 days every 14 days (in combination with bevacizumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22778320']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22778320'])">Ref</a></span>) <b>or</b> 150 mg/m<sup>2</sup> once daily for 7 days every 14 days (in combination with everolimus) for 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23733618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23733618'])">Ref</a></span>) <b>or</b> 150 mg/m<sup>2</sup> once daily for 7 days every 14 days (in combination with thalidomide) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16421420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16421420'])">Ref</a></span>) <b>or</b> 200 mg/m<sup>2</sup> (maximum dose: 400 mg) once daily on days 10 to 14 (5 days) of a 28-day treatment cycle (in combination with capecitabine) for up to 13 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36260828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36260828'])">Ref</a></span>) <b>or</b> 175 to 200 mg/m<sup>2</sup> once daily (at bedtime) on days 10 to 14 (5 days) of a 28-day treatment cycle (in combination with capecitabine) until maximum response, disease progression, or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20824724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20824724'])">Ref</a></span>) <b>or</b> (single-agent therapy) 100 to 150 mg/m<sup>2</sup> once daily for 5 days of a 28-day treatment cycle in cycle 1, followed by 100 to 200 mg/m<sup>2</sup> once daily for 5 days of subsequent 28-day treatment cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17505000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17505000'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe2f15f6-7823-4d0e-8183-6652b48c33a5">Primary CNS lymphoma, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary CNS lymphoma, newly diagnosed (off-label use):</b>
<b>Oral:</b> Induction: 150 mg/m<sup>2</sup> once daily on days 7 to 11 each month for 5 months (in combination with 14-day cycles of high-dose methotrexate, leucovorin, and rituximab; temozolomide is administered during odd cycles), followed by consolidation therapy with etoposide and cytarabine; refer to protocol for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23569323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23569323'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21fe452b-0c12-48c1-af75-090967294802">Primary CNS lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary CNS lymphoma, relapsed or refractory (off-label use):</b>
<b>Oral:</b> 150 mg/m<sup>2</sup> once daily for 5 days every 28 days, initially in combination with rituximab (for 4 cycles), followed by temozolomide monotherapy: 150 mg/m<sup>2</sup> once daily for 5 days every 28 days for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15221999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15221999'])">Ref</a></span>) <b>or</b> 150 mg/m<sup>2</sup> once daily on days 1 to 7 and 15 to 21 every 28 days (initially in combination with rituximab for 1 or 2 cycles), followed by temozolomide maintenance monotherapy: 150 mg/m<sup>2</sup> once daily for 5 days every 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15365145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15365145'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="17407144-6d24-4f46-b3c1-be7771bbde34">Soft tissue sarcomas, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Soft tissue sarcomas, advanced (off-label use):</b>
<b>Oral:</b> 75 mg/m<sup>2</sup> once daily for 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16134177']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16134177'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="435acdf1-6a68-4c4c-acd8-f737d132328d">Soft tissue sarcoma, hemangiopericytoma/solitary fibrous tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Soft tissue sarcoma, hemangiopericytoma/solitary fibrous tumor (off-label use): Oral:</b> 150 mg/m<sup>2</sup> once daily on days 1 to 7 and days 15 to 21 of a 28-day treatment cycle (in combination with bevacizumab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21480200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21480200'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991654"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥36 mL/minute/m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;36 mL/minute/m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage kidney disease on dialysis: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988956"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment prior to treatment initiation:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Turcotte-Pugh classes A, B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Turcotte-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F225239"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (55%), skin rash (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (27%), constipation (22% to 33%), diarrhea (10% to 16%; grades ≥3: 1% to 2%), nausea (49% to 53%; grades ≥3: 1% to 10%), vomiting (29% to 42%; grades ≥3: 2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased neutrophils (grades 3/4: 14%), leukopenia (grades 3/4: 11%), lymphocytopenia (grades 3/4: 55%), thrombocytopenia (5%; grades 3/4: 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Viral infection (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (13%), ataxia (11%), dizziness (12%), fatigue (34% to 61%; severe: 13%), headache (23% to 41%; severe: 5%), hemiparesis (18%), seizure (6% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (&lt;10%), pruritus (&lt;10%), xeroderma (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercorticoidism (&lt;10%), weight gain (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (&lt;10%), dysgeusia (&lt;10%), dysphagia (&lt;10%), stomatitis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Mastalgia (females: &lt;10%), urinary frequency (&lt;10%), urinary incontinence (&lt;10%), urinary tract infection (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (&lt;10%), amnesia (10%), anxiety (&lt;10%), confusion (&lt;10%), depression (&lt;10%), drowsiness (&lt;10%), insomnia (10%), memory impairment (&lt;10%), paresis (&lt;10%), paresthesia (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;10%), back pain (&lt;10%), myalgia (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (&lt;10%), diplopia (&lt;10%), visual disturbance (including visual deficit, vision changes: &lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (&lt;10%), dyspnea (&lt;10%), pharyngitis (&lt;10%), sinusitis (&lt;10%), upper respiratory tract infection (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hematologic &amp; oncologic: Anemia, malignant neoplasm (secondary; including secondary acute myelocytic leukemia), myelodysplastic syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes insipidus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Pancytopenia (may be prolonged)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, hepatotoxicity (severe), hyperbilirubinemia, increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Opportunistic infection</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including erythema at injection site, hematoma at injection site, injection-site pruritus, irritation at injection site, pain at injection site, petechia, swelling at injection site, warm sensation at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis, pneumonia due to <i>Pneumocystis jirovecii</i>, pneumonitis, pulmonary alveolitis, pulmonary fibrosis</p></div>
<div class="block coi drugH1Div" id="F225252"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serious hypersensitivity to temozolomide or any component of the formulation; serious hypersensitivity to dacarbazine (both temozolomide and dacarbazine are metabolized to 5-[3-methyl-triazene-1-yl]-imidazole-4-carboxamide [MTIC]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Not recommended in patients with severe myelosuppression.</p></div>
<div class="block war drugH1Div" id="F225236"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Myelosuppression (including leukopenia, anemia, and pancytopenia), including fatal outcomes, may occur. In the refractory anaplastic astrocytoma study, myelosuppression usually occurred during the first few therapy cycles and was not typically cumulative; the median platelet nadir onset occurred at 26 days (range: 21 to 40 days) and the median neutrophil nadir onset occurred at 28 days (range: 1 to 44 days). Some patients required hospitalization, blood transfusions, and/or discontinuation due to hematologic toxicity. An increased risk of hematologic toxicity has been reported in older adults and female patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatotoxicity has been reported; may be severe or fatal. Postmarketing reports of hepatotoxicity have included liver function abnormalities, hepatitis, hepatic failure, cholestasis, hepatitis cholestasis, jaundice, cholelithiasis, hepatic steatosis, hepatic necrosis, hepatic lesion, and hepatic encephalopathy (Sarganas 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Allergic reactions (including anaphylaxis) have been observed with temozolomide.</p>
<p style="text-indent:-2em;margin-left:4em;">• <i>Pneumocystis</i> pneumonia: <i>Pneumocystis jirovecii</i> pneumonia (PCP) has been reported with temozolomide; the risk is increased in those receiving corticosteroids or with longer temozolomide treatment regimens. Provide PCP prophylaxis to all patients with newly diagnosed glioblastoma receiving concomitant phase radiotherapy; continue PCP prophylaxis in patients with lymphopenia until lymphopenia resolves to ≤ grade 1.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancies: The incidence of secondary malignancies is increased with temozolomide-containing regimens. Cases of myelodysplastic syndromes and secondary malignancies, including myeloid leukemia, have been reported following treatment with temozolomide.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥70 years of age experienced a higher incidence of grade 4 neutropenia and thrombocytopenia in cycle 1 (compared to patients &lt;70 years of age).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration schedule: Administration schedule (intermittent versus continuous) varies based on indication.</p>
<p style="text-indent:-2em;margin-left:4em;">• Temozolomide resistance: Increased O-6-methylguanine-DNA methyltransferase (MGMT) activity/levels within tumor tissue is associated with temozolomide resistance. Glioblastoma patients with decreased levels (due to methylated MGMT promoter) may be more likely to benefit from the combination of radiation therapy and temozolomide (Hegi 2008; Stupp 2009). Determination of MGMT status may be predictive for response to alkylating agents.</p></div>
<div class="block foc drugH1Div" id="F225246"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Temodar: 5 mg [DSC] [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Temodar: 20 mg [DSC], 100 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Temodar: 140 mg [DSC] [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Temodar: 180 mg [DSC], 250 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Temodar: 100 mg (1 ea) [pyrogen free; contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F225232"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F225254"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Temozolomide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $12.52 - $14.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $50.46 - $57.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $252.29 - $287.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">140 mg (per each): $353.21 - $402.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $454.13 - $517.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $630.91 - $719.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Temodar Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1,203.73</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868347"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Temodal: 5 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Temodal: 20 mg, 100 mg [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Temodal: 140 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Temodal: 250 mg [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg</p></div>
<div class="block exp drugH1Div" id="F4152326"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>1.25 mg/mL Oral Solution</b></p>
<p style="text-indent:-2em;margin-left:4em;">Reconstitute temozolomide powder for injection according to the manufacturer's labeling, resulting in a concentration of 2.5 mg/mL; further dilute 1:1 with distilled water, resulting in a final concentration of 1.25 mg/mL. Stable for 13 weeks refrigerated. Prior to administration, dose may be mixed with a small amount of apple juice or cola if needed.</p>
<div class="reference">Nygren H, Eksborg S. Stability of temozolomide in solutions aimed for oral treatment prepared from a commercially available powder for infusion. <i>Pharm Methods</i>. 2012;3(1):1-3. doi:10.4103/2229-4708.97700</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>10 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 10 mg/mL temozolomide oral suspension may be compounded in a vertical flow hood. Mix the contents of ten 100 mg capsules and 500 mg of povidone K-30 powder in a glass mortar; add 25 mg anhydrous citric acid dissolved in 1.5 mL purified water and mix to a uniform paste; mix while adding 50 mL Ora-Plus in incremental proportions. Transfer to an amber plastic bottle, rinse mortar 4 times with small portions of either Ora-Sweet or Ora-Sweet SF, and add quantity of Ora-Sweet or Ora-Sweet SF sufficient to make 100 mL. Store in plastic amber prescription bottles; label "shake well" and "refrigerate"; include the beyond-use date. Stable at room temperature for 7 days (Ora-Sweet) or 14 days (Ora-Sweet SF), or for 60 days refrigerated (preferred).</p>
<div class="reference">Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-192.</div>
<div class="reference">Trissel LA, Yanping Z, and Koontz SE, "Temozolomide Stability in Extemporaneously Compounded Oral Suspension," <i>Int J Pharm Compound</i>, 2006, 10(5):396-9.</div>
</div>
<div class="block adip drugH1Div" id="F53568799"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">To minimize the risk of a wrong dose error, each strength of temozolomide must be packaged and dispensed in a separate vial or in its original glass bottle. Label each container with the appropriate number of capsules to be taken each day.</p></div>
<div class="block admp drugH1Div" id="F52613903"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Temozolomide is associated with a low or moderate emetic potential depending on dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637','lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637','lexi-content-ref-30729654'])">Ref</a></span>); antiemetics may be recommended to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Swallow capsule intact with a glass of water; do not chew; per manufacturer's labeling, capsules should not be opened. However, capsules are large and often cannot be swallowed by pediatric patients; if patient is unable to swallow capsule, open capsule and dissolve in acidic juice (eg, orange juice, apple juice) or applesauce, taking precautions to avoid exposure to the cytotoxic agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16047361','lexi-content-ref-23630159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16047361','lexi-content-ref-23630159'])">Ref</a></span>); an extemporaneously prepared oral solution or suspension may also be used. Administer temozolomide on an empty stomach or at bedtime to reduce the incidence of nausea and vomiting; absorption is affected by food; may administer with food as long as food intake and administration are performed at the same time each day to ensure consistent bioavailability. Do not repeat if vomiting occurs after dose is administered; wait until the next scheduled dose.</p></div>
<div class="block adm drugH1Div" id="F225249"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Temozolomide is associated with a moderate or high emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>); antiemetics are recommended to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer at the same time each day. Swallow capsules whole with a glass of water; do not open, chew, or dissolve capsule contents. Administer consistently with respect to food (either consistently fasting or nonfasting). Administer on an empty stomach and/or at bedtime to reduce nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In some glioblastoma studies of temozolomide with concurrent radiation therapy, temozolomide was administered in a fasted state, 1 hour prior to radiotherapy (on radiotherapy days), and either in the morning or per institutional protocol on nonradiotherapy days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28296618','lexi-content-ref-11870182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28296618','lexi-content-ref-11870182'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">If capsules are accidently opened or damaged, avoid inhalation or contact with skin or mucous membranes; if contact with powder occurs, wash area immediately with water. Follow appropriate hazardous drug handling procedures if capsules must be opened or the contents must be dissolved.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse via an infusion pump over 90 minutes (shorter or longer infusion times may result in suboptimal dosing). Flush line before and after administration. May be administered through the same IV line as sodium chloride 0.9%; do not administer other solutions or medications through the same IV line.</p></div>
<div class="block hazard drugH1Div" id="F49132830"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F225265"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store intact vials at 2°C to 8°C (36°F to 46°F). Reconstituted vials may be stored for up to 14 hours at room temperature of 25°C (77°F); infusion must be completed within 14 hours of reconstitution.</p></div>
<div class="block usep drugH1Div" id="F53569047"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of refractory anaplastic astrocytoma with progression after initial therapy with a nitrosourea and procarbazine (FDA approved in adults); treatment of newly-diagnosed glioblastoma multiforme (initially in combination with radiotherapy, then as maintenance treatment) (FDA approved in adults); has also been used in neuroblastoma (relapsed or refractory), Ewing sarcoma (recurrent or progressive), and solid tumors (relapsed or refractory)</p></div>
<div class="block mst drugH1Div" id="F3402099"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Temodar may be confused with Tambocor</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Temozolomide may be confused with temsirolimus</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300110"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6223210"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May enhance the adverse/toxic effect of Temozolomide. Valproate Products may increase the serum concentration of Temozolomide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F225266"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food reduces rate and extent of absorption. Management: Administer consistently either with food or without food (was administered in studies under fasting and nonfasting conditions).</p></div>
<div class="block rep_considerations drugH1Div" id="F53623776"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for 6 months after the last temozolomide dose. Patients with partners who are pregnant or could become pregnant should use condoms during treatment and for 3 months after the last temozolomide dose.</p>
<p style="text-indent:0em;margin-top:2em;">Males should not donate semen during treatment and for 3 months after the last temozolomide dose.</p>
<p style="text-indent:0em;margin-top:2em;">Temozolomide may impair fertility; limited data indicate changes in sperm parameters during temozolomide treatment; however, there is no information in duration or reversibility of sperm changes.</p></div>
<div class="block pri drugH1Div" id="F225255"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and findings in animal reproduction studies, in utero exposure to temozolomide may cause fetal harm.</p></div>
<div class="block mopp drugH1Div" id="F53569046"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Refer to pediatric-specific protocols. CBC with differential and platelets (prior to each cycle; at or within 48 hours of day 22 and weekly until ANC &gt;1,500/mm<sup>3</sup> and platelets &gt;100,000/mm<sup>3</sup>. Monitor liver function tests at baseline, halfway through the first cycle, prior to each subsequent cycle, and at ~2 to 4 weeks after the last dose. Monitor for signs/symptoms of pneumocystis pneumonia. Monitor adherence.</p></div>
<div class="block pha drugH1Div" id="F225235"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Temozolomide is a prodrug which is rapidly and nonenzymatically converted to the active alkylating metabolite MTIC [(methyl-triazene-1-yl)-imidazole-4-carboxamide]; this conversion is spontaneous, nonenzymatic, and occurs under physiologic conditions in all tissues to which it distributes (Marchesi 2007; Villano 2009). The cytotoxic effects of MTIC are manifested through alkylation (methylation) of DNA at the O<sup>6</sup>, N<sup>7</sup> guanine positions which lead to DNA double strand breaks and apoptosis (Villano 2009). Temozolomide is noncell cycle specific (Marchesi 2007).</p></div>
<div class="block phk drugH1Div" id="F225251"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid and complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Parent drug: 0.4 L/kg. Temozolomide penetrates blood-brain barrier; cerebrospinal fluid levels are ~35% to 39% of plasma levels (Yung 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 15%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Prodrug, hydrolyzed to the active form, 5-(3-methyl-triazene-1-yl)-imidazole-4-carboxamide (MTIC); MTIC is eventually eliminated as CO<sub>2</sub> and 5-aminoimidazole-4-carboxamide (AIC), a natural constituent in urine; CYP isoenzymes play only a minor role in metabolism (of temozolomide and MTIC).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 100% (on a mg-per-mg basis, IV temozolomide, infused over 90 minutes, is bioequivalent to an oral dose).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Mean: Parent drug: Children: 1.7 hours; Adults: 1.8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral: Median: 1 hour; with food (high-fat meal): 2.25 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~38%; parent drug 6%; AIC 12%); feces &lt;1%.</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: ~5.5 L/hour/m<sup>2</sup>; pediatric subjects 3 to 17 years have similar temozolomide clearance as adults.</p></div>
<div class="block phksp drugH1Div" id="F52180998"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Sex: Females may have an ~5% lower temozolomide clearance (adjusted for body surface area) than males.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F225257"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Tegozol | Temodal</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Clitech | Kemtax | Rumalar | Temodal | Temola | Temonova | Temoxan | Temozolomida gp pharm | Terbai | Tezulina | Varizolamida | Zolom</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temomedac | Temozolomid accord | Temozolomid ratiopharm | Temozolomid sandoz | Temozolomid stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo temozolomide | Astromide | Orion temozolomide | Temizole | Temodal | Temolide | Temozolomide alphapharm | Temozolomide an | Temozolomide juno</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Temonix</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temomedac | Temozolomide accord | Temozolomide EG | Temozolomide hospira | Temozolomide Mylan | Temozolomide sandoz | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Blastomat | Nogron | Temodal</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Telma | Temodal | Temolida | Temozod | Temozolomida | Zabrux</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temozolomid accord | Temozolomid labatec | Temozolomid Medac | Temozolomid teva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dralitem | Mozola | Temodal | Varizolomida</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Di qing | Temodal</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dralitem | Hb oncobrain | Tedolix | Temaz | Temitoma | Temodal | Temozolomida | Tensacton | Tripzol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo temozolomid | Temodal | Temomedac | Temozolomide accord | Temozolomide glenmark | Temozolomide sandoz | Temozolomide sun | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temomedac | Temozo cell | Temozolomid accord | Temozolomid Fair Med | Temozolomid Hexal | Temozolomid Hospira | Temozolomid ratiopharm | Temozolomid teva | Temozolomide fair med | Temozolomide ratiopharm | Temozolomide sun</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dralitem | Telamid-100 | Telamid-20 | Temodal</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Tocitrap</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Blastomat | Temodal | Temozolomide accord | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Temodal</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temomedac | Temozolomida hospira | Temozolomida sun | Temozolomida teva</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Temozol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temomedac | Temozolamid ratiopharm | Temozolomid ratiopharm | Temozolomid teva | Temozolomide accord | Temozolomide hospira | Temozolomide sandoz | Temozolomide sun | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temozolamide teva | Temozolomide accord | Temozolomide Mylan | Temozolomide sun</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temomedac | Temozolomide accord | Temozolomide Actavis</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ridoca | Temodal | Temomedac | Temozolomide accord | Temozolomide sandoz | Temozolomide/Teva | Tezolamet</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Temodal</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Blastomat | Temazol | Temodal</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Blastomat | Nogron | Temodal | Temostad | Temozolomide sandoz | Temozolomide sun | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temotero | Teroza</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temozolomide accord | Temozolomide clonmel | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Temodal</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Gbmt | Gliogen | Gliotem | Glioz | Glisoma | Glistroma | Strimodal | Tabze | Temcad | Temcure | Temo trust | Temodal | Temoglan | Temolon | Temoloz | Temonat | Temorel | Temoside | Temotec | Temotero | Temoway | Temozam | Temozol | Zolotem</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temozolomide accord | Temozolomide Crinos | Temozolomide sandoz | Temozolomide sun | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Tegozol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Temodal</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Emzolam | Temodal | Temotero</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Astrodal | Temodal | Temolam | Temolde | Temozol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Accotim | Temodal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Blastomat | Temodal | Temozolomide accord | Temozolomide sandoz | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temozolomide accord | Temozolomide sandoz | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Blastomat | Temodal | Temozolomide accord | Temozolomide sandoz | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temozolomide zenith</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Byaimid | Niman | Paxublin | Rubrum asf | Temodal | Temozolomida | Tera caz | Termozepal | Timzomide | Zuriphar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temozam</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temozolomide hospira | Temozolomide ratiopharm | Temozolomide sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temomedac | Temozolomid ratiopharm | Temozolomide accord | Temozolomide hospira | Temozolomide sun | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo temozolomide | Orion temozolomide | Temaccord | Temodal | Temozolomide accord | Temozolomide amneal</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dralitem | Mozola | Nilactin | Temodal | Temozolomida | Tocitrap</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Emzolam | Gliotem | Temodal | Temosanz 100 | Temotero | Temovex | Temozam</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Midizol | Temoeirgen | Temomedac | Temonat</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Blastomat | Temodal | Temomedac | Temostad | Temozolomide accord | Temozolomide fair med | Temozolomide glenmark | Temozolomide polpharma | Temozolomide sun | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Temodar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temomedac | Temozolomida accord | Temozolomida Stada | Temozolomida teva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dralitem | Temola | Temolon | Temozolamida libra | Temozolomida imedic | Temozolomida varifarma | Temozolomida vmg | Tezulina | Tocitrap | Zolom</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Temodal</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Blastomat | Brastoryn | Temozolomida accord | Temozolomida teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Astroglif | Temcital | Temodal | Temomid | Temozoleks | Temozolomide rus | Temozolomide teva | Temozolomide tl | Tezalom</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lagona | Tegozol | Temodal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temomedac | Temozolomi accord | Temozolomid Ebb | Temozolomid stada | Temozolomide accord | Temozolomide hospira | Temozolomide sandoz | Temozolomide sun | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Temodal</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Temomedac | Temozolomid accord | Temozolomid sandoz | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Nogron | Temodal | Temomedac | Temostad | Temozolomid ratiopharm | Temozolomide accord | Temozolomide sandoz | Temozolomide sun | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Temodal | Zolotem</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Tegozol | Temo | Temodal | Temomedac</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Midizol | Temodal | Temomid | Temozolid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tamos | Temodal</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Glyosomid | Temodal | Temozolomide teva</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Temozolamida | Temozolomida | Tocitrap</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord Temozolomide | Temintas | Temoxol | Tezmyl</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Temodal</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Temotero</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USPNF.2020">
<a name="USPNF.2020"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11718258">
<a name="11718258"></a>Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. <i>J Neurooncol</i>. 2001;53(3):259-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/11718258/pubmed" id="11718258" target="_blank">11718258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15169796">
<a name="15169796"></a>Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. <i>J Clin Oncol</i>, 2004;22(11):2101-2107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/15169796/pubmed" id="15169796" target="_blank">15169796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21115869">
<a name="21115869"></a>Bagatell R, London WB, Wagner LM, et al, “Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study,” <i>J Clin Oncol</i>, 2011, 29(2):208-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/21115869/pubmed" id="21115869" target="_blank">21115869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32328662">
<a name="32328662"></a>Balana C, Vaz MA, Manuel Sepúlveda J, et al. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). <i>Neuro Oncol</i>. 2020;22(12):1851-1861. doi:10.1093/neuonc/noaa107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/32328662/pubmed" id="32328662" target="_blank">32328662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28371907">
<a name="28371907"></a>Blumenthal DT, Gorlia T, Gilbert MR, et al. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro Oncol</i>. 2017;19(8):1119-1126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/28371907/pubmed" id="28371907" target="_blank">28371907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11300335">
<a name="11300335"></a>Brada M, Hoang-Xuan K, Rampling R, et al, “Multicenter Phase II Trial of Temozolomide in Patients With Glioblastoma Multiforme at First Relapse,” <i>Ann Oncol</i>, 2001, 12(2):259-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/11300335/pubmed" id="11300335" target="_blank">11300335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20855843">
<a name="20855843"></a>Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. <i>J Clin Oncol</i>. 2010;28(30):4601-4608.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/20855843/pubmed" id="20855843" target="_blank">20855843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16954518">
<a name="16954518"></a>Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. <i>J Clin Oncol</i>. 2006;24(29):4746-4753.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/16954518/pubmed" id="16954518" target="_blank">16954518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19637327">
<a name="19637327"></a>Casey DA, Wexler LH, Merchant MS, et al, “Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience,” <i>Pediatr Blood Cancer</i>, 2009, 53(6):1029-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/19637327/pubmed" id="19637327" target="_blank">19637327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23733618">
<a name="23733618"></a>Chan JA, Blaszkowsky L, Stuart K, et al. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. <i>Cancer</i>. 2013;119(17):3212-3218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/23733618/pubmed" id="23733618" target="_blank">23733618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22778320">
<a name="22778320"></a>Chan JA, Stuart K, Earle CC, et al, “Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors,” <i>J Clin Oncol</i>, 2012, 30(24):2963-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/22778320/pubmed" id="22778320" target="_blank">22778320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11300333">
<a name="11300333"></a>Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. <i>Ann Oncol</i>. 2001;12(2):249-254.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/11300333/pubmed" id="11300333" target="_blank">11300333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21339192">
<a name="21339192"></a>Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. <i>Neuro Oncol</i>. 2011;13(3):317-323. doi: 10.1093/neuonc/noq191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/21339192/pubmed" id="21339192" target="_blank">21339192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16047361">
<a name="16047361"></a>De Sio L, Milano GM, Castellano A, et al. Temozolomide in resistant or relapsed pediatric solid tumors. <i>Pediatr Blood Cancer</i>. 2006;47(1):30-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/16047361/pubmed" id="16047361" target="_blank">16047361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24021349">
<a name="24021349"></a>Di Giannatale A, Dias-Gastellier N, Devos A, et al. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. <i>Eur J Cancer</i>. 2014;50(1):170-177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/24021349/pubmed" id="24021349" target="_blank">24021349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17505000">
<a name="17505000"></a>Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. <i>Clin Cancer Res</i>. 2007;13(10):2986-2991.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/17505000/pubmed" id="17505000" target="_blank">17505000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15365145">
<a name="15365145"></a>Enting RH, Demopoulos A, DeAngelis LM, et al, “Salvage Therapy for Primary CNS Lymphoma With a Combination of Rituximab and Temozolomide,” <i>Neurology</i>, 2004, 63(5):901-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/15365145/pubmed" id="15365145" target="_blank">15365145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25680596">
<a name="25680596"></a>Fisher BJ, Hu C, Macdonald DR, et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. <i>Int J Radiat Oncol Biol Phys</i>. 2015;91(3):497-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/25680596/pubmed" id="25680596" target="_blank">25680596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20406900">
<a name="20406900"></a>Gan HK, Rosenthal MA, Dowling A, et al. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. <i>Neuro Oncol</i>. 2010;12(5):500-507.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/20406900/pubmed" id="20406900" target="_blank">20406900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16134177">
<a name="16134177"></a>Garcia del Muro X, Lopez-Pousa A, Martin J, et al, “A Phase II Trial of Temozolomide as a 6-Week, Continuous, Oral Schedule in Patients With Advanced Soft Tissue Sarcoma: A Study by the Spanish Group for Research on Sarcomas,” <i>Cancer</i>, 2005, 104(8):1706-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/16134177/pubmed" id="16134177" target="_blank">16134177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27022122">
<a name="27022122"></a>Glass J, Won M, Schultz CJ, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. <i>J Clin Oncol</i>. 2016;34(14):1620-1625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/27022122/pubmed" id="27022122" target="_blank">27022122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18757334">
<a name="18757334"></a>Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. <i>J Clin Oncol.</i> 2008;26(25):4189-4199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/18757334/pubmed" id="18757334" target="_blank">18757334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16421420">
<a name="16421420"></a>Kulke MH, Stuart K, Enzinger PC, et al. Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors. <i>J Clin Oncol.</i> 2006;24(3):401-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/16421420/pubmed" id="16421420" target="_blank">16421420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36260828">
<a name="36260828"></a>Kunz PL, Graham NT, Catalano PJ, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). <i>J Clin Oncol</i>. 2023;41(7):1359-1369. doi:10.1200/JCO.22.01013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/36260828/pubmed" id="36260828" target="_blank">36260828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21049517">
<a name="21049517"></a>Kushner BH, Kramer K, Modak S, Cheung NK. High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan. <i>Pediatr Blood Cancer</i>. 2011;56(3):403-408. doi: 10.1002/pbc.22855.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/21049517/pubmed" id="21049517" target="_blank">21049517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23085829">
<a name="23085829"></a>Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK. 5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma. <i>Bone Marrow Transplant</i>. 2013;48(5):642-645. doi: 10.1038/bmt.2012.202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/23085829/pubmed" id="23085829" target="_blank">23085829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21275495">
<a name="21275495"></a>Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-192. doi:10.1592/phco.31.2.164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/21275495/pubmed" id="21275495" target="_blank">21275495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17897837">
<a name="17897837"></a>Marchesi F, Turriziani M, Tortorelli G, et al, “Triazene Compounds: Mechanism of Action and Related DNA Repair Systems,” <i>Pharmacol Res</i>, 2007, 56(4):275-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/17897837/pubmed" id="17897837" target="_blank">17897837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10623706">
<a name="10623706"></a>Middleton MR, Grob JJ, Aaronson N, et al. Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma. <i>J Clin Oncol.</i> 2000;18(1):158-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/10623706/pubmed" id="10623706" target="_blank">10623706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19011763">
<a name="19011763"></a>Mikkelsen T, Doyle T, Anderson J, et al. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. <i>J Neurooncol.</i> 2009;92(1):57-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/19011763/pubmed" id="19011763" target="_blank">19011763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17705175">
<a name="17705175"></a>Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 Study of Temozolomide in Children and Adolescents With Recurrent Central Nervous System Tumors: A Report From the Children's Oncology Group. <i>Cancer.</i> 2007;110(7):1542-1550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/17705175/pubmed" id="17705175" target="_blank">17705175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23243055">
<a name="23243055"></a>Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro Oncol</i>. 2013;15(2):242-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/23243055/pubmed" id="23243055" target="_blank">23243055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21480200">
<a name="21480200"></a>Park MS, Patel SR, Ludwig JA, et al. Activity of Temozolomide and Bevacizumab in the Treatment of Locally Advanced, Recurrent, and Metastatic Hemangiopericytoma and Malignant Solitary Fibrous Tumor. <i>Cancer. </i>2011;117(21):4939-4947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/21480200/pubmed" id="21480200" target="_blank">21480200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi: 10.1002/pbc.27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20308655">
<a name="20308655"></a>Perry JR, Bélanger K, Mason WP, et al. Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study. <i>J Clin Oncol.</i> 2010;28(12):2051-2057.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/20308655/pubmed" id="20308655" target="_blank">20308655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28296618">
<a name="28296618"></a>Perry JR, Laperriere N, O'Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. <i>N Engl J Med</i>. 2017;376(11):1027-1037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/28296618/pubmed" id="28296618" target="_blank">28296618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17082887">
<a name="17082887"></a>Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. <i>J Neurooncol</i>. 2007;82(3):281-288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/17082887/pubmed" id="17082887" target="_blank">17082887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21747120">
<a name="21747120"></a>Querfeld C, Rosen ST, Guitart J, et al. Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sezary Syndrome: Correlation With O<sup>6</sup>-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins. <i>Clin Cancer Res. </i> 2011;17(17):5748-5754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/21747120/pubmed" id="21747120" target="_blank">21747120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi:10.1093/annonc/mdw270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23569323">
<a name="23569323"></a>Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). <i>J Clin Oncol</i>. 2013;31(25):3061-3068. doi: 10.1200/JCO.2012.46.9957.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/23569323/pubmed" id="23569323" target="_blank">23569323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22394496">
<a name="22394496"></a>Sarganas G, Orzechowski HD, Klimpel A, et al. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. <i>Neuro Oncol</i>. 2012;14(5):541-546. doi: 10.1093/neuonc/nos056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/22394496/pubmed" id="22394496" target="_blank">22394496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19767314">
<a name="19767314"></a>Siena S, Crinò L, Danova M, et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. <i>Ann Oncol</i>. 2010;21(3):655-661.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/19767314/pubmed" id="19767314" target="_blank">19767314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20824724">
<a name="20824724"></a>Strosberg JR, Fine RL, Choi J, et al, “First-line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas,” <i>Cancer</i>, 2011, 117(2):268-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/20824724/pubmed" id="20824724" target="_blank">20824724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11870182">
<a name="11870182"></a>Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. <i>J Clin Oncol</i>. 2002;20(5):1375-1382. doi:10.1200/JCO.2002.20.5.1375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/11870182/pubmed" id="11870182" target="_blank">11870182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19269895">
<a name="19269895"></a>Stupp R, Hegi ME, Mason WP, et al, “Effects of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-year Analysis of the EORTC-NCIC Trial,” <i>Lancet Oncol</i>, 2009, 10(5):459-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/19269895/pubmed" id="19269895" target="_blank">19269895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15758009">
<a name="15758009"></a>Stupp R, Mason WP, van den Bent MJ, et al, “Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma,” <i>N Engl J Med</i>, 2005, 352(10):987-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/15758009/pubmed" id="15758009" target="_blank">15758009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Temodal.1">
<a name="Temodal.1"></a>Temodal (temozolomide) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Temodar.1">
<a name="Temodar.1"></a>Temodar (temozolomide) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23974320">
<a name="23974320"></a>Trissel LA, Zhang Y, Koontz SE. Temozolomide Stability in Extemporaneously Compounded Oral Suspensions. <i>Int J Pharm Compd</i>. 2006;10(5):396-399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/23974320/pubmed" id="23974320" target="_blank">23974320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16565212">
<a name="16565212"></a>Trudeau ME, Crump M, Charpentier D, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). <i>Ann Oncol</i>. 2006;17(6):952-956.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/16565212/pubmed" id="16565212" target="_blank">16565212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28801186">
<a name="28801186"></a>van den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet</i>. 2017;390(10103):1645-1653. doi:10.1016/S0140-6736(17)31442-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/28801186/pubmed" id="28801186" target="_blank">28801186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34000245">
<a name="34000245"></a>van den Bent MJ, Tesileanu CMS, Wick W, et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncol</i>. 2021;22(6):813-823. doi:10.1016/S1470-2045(21)00090-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/34000245/pubmed" id="34000245" target="_blank">34000245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19543728">
<a name="19543728"></a>Villano JL, Seery TE and Bressler LR, “Temozolomide in Malignant Gliomas: Current Use and Future Targets,” <i>Cancer Chemother Pharmacol</i>, 2009, 64(4):647-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/19543728/pubmed" id="19543728" target="_blank">19543728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23630159">
<a name="23630159"></a>Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. <i>Pediatr Blood Cancer</i>. 2013;60(9):1447-1451. doi:10.1002/pbc.24547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/23630159/pubmed" id="23630159" target="_blank">23630159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16317751">
<a name="16317751"></a>Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. <i>Pediatr Blood Cancer</i>. 2007;48(2):132-139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/16317751/pubmed" id="16317751" target="_blank">16317751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17664483">
<a name="17664483"></a>Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. <i>J Clin Oncol</i>. 2007;25(22):3357-3361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/17664483/pubmed" id="17664483" target="_blank">17664483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19901110">
<a name="19901110"></a>Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. <i>J Clin Oncol</i>. 2009;27(35):5874-5880.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/19901110/pubmed" id="19901110" target="_blank">19901110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15221999">
<a name="15221999"></a>Wong ET, Tishler R, Barron L, et al, “Immunochemotherapy With Rituximab and Temozolomide for Central Nervous System Lymphomas,” <i>Cancer</i>, 2004, 101(1):139-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/15221999/pubmed" id="15221999" target="_blank">15221999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10944597">
<a name="10944597"></a>Yung WK, Albright RE, Olson J, et al, “A Phase II Study of Temozolomide vs Procarbazine in Patients With Glioblastoma Multiforme at First Relapse,” <i>Br J Cancer</i>, 2000, 83(5):588-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/10944597/pubmed" id="10944597" target="_blank">10944597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10561351">
<a name="10561351"></a>Yung WK, Prados MD, Yaya-Tur R, et al, “Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse,” <i>J Clin Oncol</i>, 1999, 17(9):2762-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/10561351/pubmed" id="10561351" target="_blank">10561351</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12823 Version 363.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
